Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.380
+0.020 (1.47%)
At close: Nov 13, 2025, 4:00 PM EST
1.350
-0.030 (-2.17%)
After-hours: Nov 13, 2025, 7:14 PM EST
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$698,222
Market Cap
11.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% |
| Dec 31, 2023 | 15 | 0 | - |
| Dec 31, 2022 | 15 | 0 | - |
| Dec 31, 2021 | 15 | -3 | -16.67% |
| Dec 31, 2020 | 18 | 2 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNGX News
- 6 days ago - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 6 weeks ago - Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 6 weeks ago - Soligenix Announces Closing of $7.5 Million Public Offering - PRNewsWire
- 6 weeks ago - Soligenix Announces Pricing of $7.5 Million Public Offering - PRNewsWire
- 7 weeks ago - Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor - PRNewsWire
- 2 months ago - Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses - PRNewsWire